Related Experiment Videos

Update on randomized clinical trials impacting clinical care in pediatric cardiac intensive care

Sarah Tabbutt1, Chitra Ravishankar

  • 1Division of Cardiology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. tabbutt@email.chop.edu

Congenital Heart Disease
|April 2, 2008
PubMed

Insights

Conducting clinical trials for congenital heart disease in children is difficult due to small patient groups and varied treatments. This review covers challenges and findings from trials on perioperative care for these young patients.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Surgery
  • Clinical Trial Design

Background:

  • Congenital heart disease (CHD) affects infants and children, necessitating complex surgical interventions.
  • Clinical trials in pediatric CHD are crucial for optimizing perioperative care but face significant hurdles.

Purpose of the Study:

  • To summarize the inherent challenges in conducting clinical trials for pediatric congenital heart disease.
  • To review the outcomes of single-center and multicenter trials focused on perioperative care in pediatric CHD surgery.

Main Methods:

  • The study reviews existing literature on clinical trials in pediatric CHD.
  • It specifically examines challenges such as low patient numbers, management variations, and funding limitations.
  • Results from various single-center and multicenter trials are synthesized.

Main Results:

  • Clinical trials for pediatric CHD are hampered by insufficient statistical power due to small patient cohorts.
  • Variability in institutional management strategies complicates the development of standardized multicenter protocols.
  • Despite challenges, single-center and multicenter trials provide valuable insights into perioperative care.

Conclusions:

  • Overcoming challenges in pediatric CHD clinical trials requires innovative approaches to study design and collaboration.
  • Further research and funding are essential to advance the perioperative care of infants and children with CHD.
  • Synthesizing results from existing trials is vital for improving treatment strategies.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...